Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reata Puts Hopes On Partner Study To Support Bardoxolone Resubmission

Executive Summary

Reata says partner Kyowa Kirin’s outcomes study of bardoxolone in chronic kidney disease may address the questions cited by the FDA in its complete response letter for Alport syndrome.

You may also be interested in...



Reata’s Bardoxolone Shot Down, But US FDA Advisors Offer Suggestions For Improved Study

Advisory committee unanimously votes against bardoxolone for Alport syndrome, unconvinced drug slows progression of chronic kidney disease and concerned about safety signals suggesting it could make the disease worse. However, panel offers Reata suggestions for a better-designed trial.

Unforced Error: Reata’s Decision To Ignore US FDA Endpoint Advice May Haunt Bardoxolone

Advisory committee will vet FDA argument that even though the chronic kidney disease drug met its endpoints, the trial design didn’t allow Reata to demonstrate that bardoxolone slows decline in kidney function. Safety concerns and COVID-19 trial disruptions also likely to prove worrisome.

Reata's Bardoxolone Promises Renal Benefits In Alport Syndrome

Reata is moving ahead with commercial plans as its potential first-in-class Nrf2 activator, bardoxolone methyl, meets primary and secondary endpoints in a first-year interim analysis of the Phase III CARDINAL study in patients with Alport syndrome, an inherited form of chronic kidney disease (CKD).

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC145972

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel